Sector
1080 stories · page 33 of 54
The firm said it has selected a final lead drug candidate from a short list of six DMT analogues and intends to submit the patent in the fourth quarter this year
The Canadian medical cannabis service provider saw revenues improved quarter-over-quarter after pandemic restrictions were eased
The FDA's no-objection acknowledgement letter is the highest safety rating and attestation the client can achieve for its dietary ingredient, Wellbeing Digital Sciences said
IRP Health's Reactivation program hopes to reduce patient disability in the short and long term, while giving veterans better control and understanding of their pain and health challenges
"After analyzing the operations of our TMC clinics and taking into consideration the potential for future growth, we've decided that both Hamilton and Mississauga clinics do not fully meet our expansion goals", Steven McAuley, chairman and
“We believe focusing on expanding our network of clinics will provide the company with a larger footprint to roll out new treatments as they become approved by the Food and Drug Administration and Health Canada,” said Wellbeing CEO Najla Gu
The de novo pathway is specifically designed for novel medical devices
“We’re moving fast right now to take advantage of this opportunity to be the first national brand in this space, establishing ourselves as the first name people will think of when it comes to receiving these life-changing treatments,” Irwin
“The vision we laid out for Irwin Naturals Emergence is becoming a reality with each acquisition we announce and execute,” said Irwin Naturals CEO Klee Irwin
The nutraceutical company said Entourage will manufacture the newly-formulated suite of Irwin-branded line of softgels in five different varieties: CBD, THC and three additional formulations that include both THC and another cannabinoid
“We are excited to welcome Dr Jetly to our board of directors and look forward to leveraging his expertise and insights in mental health as we continue to expand the services offered to our patients,” Pathway Health CEO Ken Yoon said
"We've seen improved outcomes first-hand from ketamine treatment in our clinics and in our clinical trials. Adding digital telehealth capabilities through KetaMD's mobile platform strengthens our position to lead the medical use of evidence
The company said it intends to use the available proceeds for general working capital and potential future acquisition purposes
The medical research company, which provides ketamine treatments for depression and related disorders, said revenue came in at C$1.49 million for fiscal 2022 compared to revenue of C$1.008 million in the year to March 31, 2021
This is the third acquisition that Irwin Naturals Emergence has completed in the past five months in an effort to build a national chain of mental health clinics providing psychedelic treatment using ketamine
The medical research company said both roles will be integral to executing the expansion of Braxia's clinical footprint, the rollout and expansion of novel ketamine and psilocybin therapy offerings, and the potential commercialization of fu
Self-care product developer still wary of supply chain issues in Chinese market
Under the agreement, KGK will perform research services, including the development of the clinical trial protocol, preparations towards the phase II clinical trials, data management and validation, statistical analysis and drafting of the f
IQ-AI said it is looking to accelerate the adoption of IB Clinic for healthcare providers through global networks
"This notice of allowance reaffirms the strength of Mindset's IP position and facilitates our ongoing development of Family 2, a highly differentiated asset in our mission to help patients with unmet needs via the discovery of optimized psy